Anzeige
Mehr »
Dienstag, 30.06.2026 - Börsentäglich über 12.000 News
Direkt neben Europas erster Lithium-Mine: Wartet hier der nächste Börsengewinner
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
308 Leser
Artikel bewerten:
(2)

Prof. Dr. Wilhelm Haverkamp Appointed Chief Medical Officer at SCIRENT

BERLIN, April 16, 2026 /PRNewswire/ -- SCIRENT announced the appointment of Prof. Dr. Wilhelm Haverkamp as Chief Medical Officer (CMO), effective immediately. In this role, Prof. Haverkamp will further strengthen SCIRENT's medical and scientific leadership and expand the company's activities in drug safety and clinical oversight.

Prof. Haverkamp is an internationally renowned expert in cardiac electrophysiology with more than three decades of scientific and clinical experience. At SCIRENT, he will contribute his extensive expertise in cardiovascular medicine and drug safety, with a particular focus on building and expanding structured safety services, including the establishment of Data Safety Monitoring Committees (DSMCs) and Clinical Event Committees (CECs).

"I am delighted to join SCIRENT and look forward to contributing my expertise to further develop innovative and high-quality drug safety services," said Prof. Haverkamp. "Ensuring patient safety and scientific excellence in clinical research is of utmost importance, and I am excited to support SCIRENT's continued growth in this field."

Over the course of his distinguished career, Prof. Haverkamp has developed internationally recognized expertise in acquired and inherited arrhythmias, heart failure, cardiomyopathies, and cardiogenetics. His research spans experimental, translational, and clinical investigations addressing disease mechanisms, diagnostics, and therapeutic strategies. In recent years, his work has increasingly focused on artificial intelligence-enhanced cardiac diagnostics, contributing to advances in precision cardiology. His scientific achievements are reflected in more than 420 peer-reviewed publications in leading cardiovascular journals.

Prof. Haverkamp is a board-certified specialist in internal medicine and cardiology. After studying medicine in Münster, he completed his specialist training at the University Hospital Münster, where he later served as senior physician and head of electrophysiology until 2002. Since then, he has been affiliated with Charité - Universitätsmedizin Berlin, where he holds a professorship in electrophysiology. At the Department of Cardiology at Campus Virchow-Klinikum, he led the electrophysiology unit until the end of 2017 and also served as acting head of the department from 2009 to 2014.

He is an active member of the German Cardiac Society and the European Society of Cardiology and contributes to clinical guidelines, scientific exchange, and educational initiatives. In addition, Prof. Haverkamp has served as principal investigator in numerous national and international clinical trials and as a member of advisory boards, data and safety monitoring boards, and clinical event committees, advising pharmaceutical companies and regulatory authorities on drug safety and cardiovascular research.

"We are very pleased to welcome such an experienced and internationally respected expert to SCIRENT," said Prof. Hans-Dirk Düngen. "Prof. Haverkamp's outstanding scientific background and deep expertise in electrophysiology and drug safety will significantly strengthen our medical capabilities and support the continued expansion of our services."

With this appointment, SCIRENT reinforces its strategic commitment to advancing clinical research quality and patient safety through strong medical leadership and innovative safety structures.

About SCIRENT

SCIRENT was founded in 2012 with the vision to help clients develop innovative therapies and medical devices for patients with cardiovascular diseases. Executing complex multi-site studies for more than 10 years, SCIRENT offers a dedicated team of experienced clinical and regulatory professionals and has developed an excellent network of experienced CV research sites in Europe and North America,

For more information about SCIRENT, please visit www.scirent.com.

Photo - https://mma.prnewswire.com/media/2957449/SCIRENT_Wilhelm_Haverkamp.jpg
Logo - https://mma.prnewswire.com/media/2957450/SCIRENT_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/prof-dr-wilhelm-haverkamp-appointed-chief-medical-officer-at-scirent-302743584.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.